<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Giugliano, Robert</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Edoxaban Noninferior to Warfarin for Stroke Prevention in AF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">15-16</style></pages><abstract><style  face="normal" font="default" size="100%">This article discusses the results of the Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) Versus Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation [ENGAGE-AF TIMI 48; Giugliano RP et al. N Engl J Med 2013] and new secondary analyses.</style></abstract><number><style face="normal" font="default" size="100%">21</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>